Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
Read about Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
Acuitas Therapeutics Honoured With Philanthropic Award
Read about Acuitas Therapeutics Honoured With Philanthropic Award
Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference
Read about Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference
Castruccio Castracani et al. (2024) “An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA” Blood.
Read about Castruccio Castracani et al. (2024) “An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA” Blood.
Chappell et al. (2024) “Use of HSC targeted LNP to generate a mouse model of lethal α-Thalassemia and treatment via lentiviral gene therapy” Blood.
DOI: 10.1182/blood.2023023349
Read about Chappell et al. (2024) “Use of HSC targeted LNP to generate a mouse model of lethal α-Thalassemia and treatment via lentiviral gene therapy” Blood.
Leonard et al. (2024) “Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA” Nature Communications.
DOI: 10.1038/s41467-024-52940-z
Read about Leonard et al. (2024) “Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA” Nature Communications.
PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA
Read about PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA
Cohen et al. (2024) “Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals” Cell.
DOI: 10.1016/j.cell.2024.07.052
Read about Cohen et al. (2024) “Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals” Cell.
Alameh et al. (2024) “A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection” Science.
DOI: 10.1126/science.adn4955
Read about Alameh et al. (2024) “A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection” Science.
Atochina-Vasserman et al. (2024) “Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection” NPJ Vaccines.
DOI: 10.1038/s41541-024-00976-z
Read about Atochina-Vasserman et al. (2024) “Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection” NPJ Vaccines.
Kafle et al. (2024) “The roles of CD4+ T cell help, sex, and dose in the induction of protective CD8+ T cells against a lethal poxvirus by mRNA-LNP vaccines” Molecular Therapy Nucleic Acids.
DOI: 10.1016/j.omtn.2024.102279
Read about Kafle et al. (2024) “The roles of CD4+ T cell help, sex, and dose in the induction of protective CD8+ T cells against a lethal poxvirus by mRNA-LNP vaccines” Molecular Therapy Nucleic Acids.
Kuzmin et al. (2024) “Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine” Nature Communications.
DOI: 10.1038/s41467-024-50774-3
Read about Kuzmin et al. (2024) “Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine” Nature Communications.